These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 4148588)
21. [Part II; standardization and normalization of dyes. 12. Introduction: relationship of the dye commission to the professional standards committee in medicine]. Fasske E Acta Histochem; 1973; Suppl 13(0):317-8. PubMed ID: 4214394 [No Abstract] [Full Text] [Related]
22. Present status of clinical pharmacology and of regulatory requirements for preclinical and clinical evaluation of new drugs in Japan. Ishizaki T; Sugita M Clin Pharmacol Ther; 1974 Sep; 16(3):577-84. PubMed ID: 4415183 [No Abstract] [Full Text] [Related]
23. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering? Purnhagen KP Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663 [No Abstract] [Full Text] [Related]
24. Medicines, governments and doctors. Dunlop D Drugs; 1972; 3(5):305-13. PubMed ID: 4652594 [No Abstract] [Full Text] [Related]
25. Drugs in the E.E.C. Lancet; 1972 Apr; 1(7757):944-5. PubMed ID: 4112105 [No Abstract] [Full Text] [Related]
26. Law, medicines and the doctor: a critical look at drug regulation. Dukes MN Curr Med Res Opin; 1973; 1(10):612-28. PubMed ID: 4778727 [No Abstract] [Full Text] [Related]
27. The value and benefits of the International Conference on Harmonisation to drug regulatory authorities: advancing harmonization for better public health. Molzon JA; Giaquinto A; Lindstrom L; Tominaga T; Ward M; Doerr P; Hunt L; Rago L Clin Pharmacol Ther; 2011 Apr; 89(4):503-12. PubMed ID: 21326288 [TBL] [Abstract][Full Text] [Related]
28. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933 [TBL] [Abstract][Full Text] [Related]
29. Control of food additives and contaminants. Goodall HM Proc Nutr Soc; 1972 May; 31(1):9-14. PubMed ID: 5048510 [No Abstract] [Full Text] [Related]
31. [Drug problems and the Common Market. Personal views]. Andersen AH Ugeskr Laeger; 1973 Jun; 135(25):1300-1. PubMed ID: 4800706 [No Abstract] [Full Text] [Related]
32. Drugs and the Washington climate. Durant TM Trans Am Clin Climatol Assoc; 1969; 80():196-204. PubMed ID: 4896316 [No Abstract] [Full Text] [Related]
33. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations]. Gleiter CH; Bieck PR Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572 [No Abstract] [Full Text] [Related]
34. Potential conflict of interest of a pharmacy and therapeutics committee member. Am J Hosp Pharm; 1989 Oct; 46(10):2047-9; discussion 2049-51. PubMed ID: 2816960 [No Abstract] [Full Text] [Related]
35. [The drug commission of German physicians and phase IV screening]. Ochsenfahrt H MMW Munch Med Wochenschr; 1983 Oct; 125(42):929-32. PubMed ID: 6417498 [No Abstract] [Full Text] [Related]
37. The International Conference on Harmonization common technical document--global submission format? Molzon JA Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749 [No Abstract] [Full Text] [Related]
38. Cardiovascular drugs: experience of the Drug Efficacy Study (DES). Freis ED; Burchell HB Circulation; 1970 Jan; 41(1):3-11. PubMed ID: 4911889 [No Abstract] [Full Text] [Related]